Developer docs
API playgroundTry for free, no card

Search company profiles

Boxer Capital

Full company profile

uuid0006rdu

Namestring
Boxer Capital
Legal namestring
Boxer Capital Management, LLC
Websiteurl
boxercap.com
Company typeenum
Private
Founded yearint
2006
Descriptiontext

Boxer Capital Management, LLC is a privately-held biotechnology investment firm headquartered in San Diego, California, founded around 2005-2006 by Aaron Davis. The firm operates as a full life cycle investor, deploying capital across private and public markets at every stage of the drug development cycle, with a thematic focus on specialized and precision medicine. The firm has invested in 74 private companies since 2014, participated in 51 liquidity events (IPOs, public listings, and acquisitions), and led or co-led 14 private rounds. Its underlying capability is a research-driven investment process conducted by a team that includes scientists with prior drug discovery and development experience across multiple therapeutic indications, combined with nearly two decades of investment experience.

The firm's business model is based on managing investment capital on behalf of its clients and earning returns through equity appreciation and realized gains on portfolio company exits. It sources deal flow primarily through professional networks and referrals rather than broad marketing, leveraging relationships with biotech founders, executives, and co-investors. Recent activity includes participation in Clene Inc.'s $28 million registered direct offering (January 2026) alongside Coastlands Capital and Vivo Capital, and co-investment in Mirador Therapeutics' $250 million Series B alongside T. Rowe Price, Fidelity, ARCH Venture Partners, OrbiMed, and Adage Capital Partners. The firm does not offer software products or technology platforms; its product is investment capital paired with strategic and scientific guidance to portfolio companies.

The firm was reorganized in 2024 from its predecessor Boxer Capital, LLC into Boxer Capital Management, LLC. Endorsements from former CEOs of Mirati Therapeutics, Prometheus Biosciences, and Pandion Therapeutics (each of which achieved major M&A exits) illustrate the firm's role as a long-term capital partner in successful precision oncology and immunology companies. Boxer Capital does not publicly disclose its AUM, revenue, fee structure, or full investor base.

Short descriptiontext

Boxer Capital Management is a San Diego-based private biotech investment firm that invests across the full drug life cycle in precision medicine companies via private and public market equity, serving as a long-term scientific and financial partner to portfolio founders.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biotechnology venture capital, precision medicine investing, biotech investment management, life sciences investment, drug development financing
Industry1 code
PRIMARYFSAAAIAA
Large-Cap Equity (Active)
Financial & Insurance/Asset & Wealth Management/Asset Management — Equity (Active)
NAICS code1 code
  • Portfolio Management and Investment Advice52394
SIC code1 code
  • Investment Advice6282
Product category
Biotechnology Venture Capital
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Investment Management Fees
TypeLicensing Royalties
Description

Boxer Capital Management operates as a full life cycle investment firm generating returns through equity investments in biotechnology companies across private and public markets. The firm earns returns on its invested capital through liquidity events including IPOs, public access, and acquisitions of portfolio companies.

boxercap.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Boxer Capital Management is a full life cycle investment firm that provides venture capital and equity investment management to specialized and precision medicine biotechnology companies across private and public markets. The firm invests across all stages of the drug life cycle — from company building and early-stage through late-stage and crossover to public — using a fundamental, research-driven approach staffed by scientists with direct drug discovery experience.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Boxer Capital Management is a biotechnology investment firm that provides venture capital and investment management services across private and public markets. The firm does not offer a product-based platform or software services; rather, it offers investment services to its clients. As a venture capital firm, Boxer Capital invests in biotechnology companies across various stages (company building, early-stage, late-stage, crossover private investments to public markets), with a focus on specialized and precision medicine. The firm's offering is structured around investment management services rather than a traditional product portfolio, and it does not have named software products, modules, or technology offerings to enumerate.

Product and service2 records
1Full Life Cycle Biotechnology Investment Management
CategoryBiotechnology venture capital and investment management
Description

Fundamental, research-based equity investment management in specialized and precision medicine biotechnology companies across private and public markets, covering company building, early-stage, late-stage, and crossover-to-public investments. Service is provided to the firm's funds and their investors.

2Private Equity Placements in Biotech Ventures
CategoryPrivate venture capital investments
Description

Direct equity investments into private biotechnology companies, including participation as lead, co-lead, or co-investor in Series funding rounds, private placements, and structured financings (such as multi-tranche registered direct offerings tied to regulatory milestones).

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Boston-based early-stage biotech fund builder with strong scientific orientation; comparable in portfolio construction philosophy to Boxer.

TypeDirect peer
Description

Healthcare-focused venture franchise with public-private crossover capabilities; overlaps with Boxer's biotech thesis investing.

TypeDirect peer
Description

Biotech-only crossover fund led by scientists/physicians investing across private and public equities; closely comparable to Boxer's specialist model.

TypeDirect peer
Description

Boston-based biotech-focused crossover fund investing across private and public markets with a science-driven diligence approach — directly comparable to Boxer's full life cycle biotech strategy.

5Baker Bros. Advisors
TypeDirect peer
Description

Long-tenured biotech-only investment manager with deep scientific bench; competes with Boxer for precision medicine equity positions across stages.

TypeDirect peer
Description

Healthcare-dedicated investment firm across private and public biotech; shares Boxer's specialization and cross-stage deployment model.

TypeDirect peer
Description

San Francisco-based healthcare and biotech specialist with crossover private-to-public investing; comparable in size and scientific thesis orientation.

TypeDirect peer
Description

Early-stage biotech venture firm with deep scientific founder relationships; overlaps with Boxer's early-stage precision medicine focus.

TypeDirect peer
Description

Biotech-focused crossover fund deploying across private rounds and public equities; mirrors Boxer's public-private, life-cycle approach.

TypeDirect peer
Description

Early-stage biotech venture firm with scientist-led diligence; comparable in scale and stage focus to Boxer's early-stage book.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment131 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Boxer Capital

Biotechnology Venture Capitalboxercap.com

Boxer Capital Management is a San Diego-based private biotech investment firm that invests across the full drug life cycle in precision medicine companies via private and public market equity, serving as a long-term scientific and financial partner to portfolio founders.

What Boxer Capital does

Boxer Capital Management, LLC is a privately-held biotechnology investment firm headquartered in San Diego, California, founded around 2005-2006 by Aaron Davis. The firm operates as a full life cycle investor, deploying capital across private and public markets at every stage of the drug development cycle, with a thematic focus on specialized and precision medicine. The firm has invested in 74 private companies since 2014, participated in 51 liquidity events (IPOs, public listings, and acquisitions), and led or co-led 14 private rounds. Its underlying capability is a research-driven investment process conducted by a team that includes scientists with prior drug discovery and development experience across multiple therapeutic indications, combined with nearly two decades of investment experience.

The firm's business model is based on managing investment capital on behalf of its clients and earning returns through equity appreciation and realized gains on portfolio company exits. It sources deal flow primarily through professional networks and referrals rather than broad marketing, leveraging relationships with biotech founders, executives, and co-investors. Recent activity includes participation in Clene Inc.'s $28 million registered direct offering (January 2026) alongside Coastlands Capital and Vivo Capital, and co-investment in Mirador Therapeutics' $250 million Series B alongside T. Rowe Price, Fidelity, ARCH Venture Partners, OrbiMed, and Adage Capital Partners. The firm does not offer software products or technology platforms; its product is investment capital paired with strategic and scientific guidance to portfolio companies.

The firm was reorganized in 2024 from its predecessor Boxer Capital, LLC into Boxer Capital Management, LLC. Endorsements from former CEOs of Mirati Therapeutics, Prometheus Biosciences, and Pandion Therapeutics (each of which achieved major M&A exits) illustrate the firm's role as a long-term capital partner in successful precision oncology and immunology companies. Boxer Capital does not publicly disclose its AUM, revenue, fee structure, or full investor base.

Boxer Capital firmographics

Firmographics
Name
Boxer Capital
Legal name
Boxer Capital Management, LLC
Website
https://boxercap.com
Company type
Private
Founded year
2006
Operating status
Operating
Headcount range
11–50 employees
Short description
Boxer Capital Management is a San Diego-based private biotech investment firm that invests across the full drug life cycle in precision medicine companies via private and public market equity, serving as a long-term scientific and financial partner to portfolio founders.
Ownership category
akta.pro rank

Boxer Capital industry classification

Industry
Product category
Biotechnology Venture Capital
NAICS
Portfolio Management and Investment Advice (52394)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSAAAIAA
Large-Cap Equity (Active)
Financial & Insurance/Asset & Wealth Management/Asset Management — Equity (Active)

Keywords

  • Biotechnology venture capital
  • Precision medicine investing
  • Biotech investment management
  • Life sciences investment
  • Drug development financing

Where Boxer Capital is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Boxer Capital business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

  1. Investment Management Fees: Boxer Capital Management operates as a full life cycle investment firm generating returns through equity investments in biotechnology companies across private and public markets. The firm earns returns on its invested capital through liquidity events including IPOs, public access, and acquisitions of portfolio companies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Boxer Capital product offering

Product offering

Core offering

Boxer Capital Management is a full life cycle investment firm that provides venture capital and equity investment management to specialized and precision medicine biotechnology companies across private and public markets. The firm invests across all stages of the drug life cycle — from company building and early-stage through late-stage and crossover to public — using a fundamental, research-driven approach staffed by scientists with direct drug discovery experience.

Product overview

Boxer Capital Management is a biotechnology investment firm that provides venture capital and investment management services across private and public markets. The firm does not offer a product-based platform or software services; rather, it offers investment services to its clients. As a venture capital firm, Boxer Capital invests in biotechnology companies across various stages (company building, early-stage, late-stage, crossover private investments to public markets), with a focus on specialized and precision medicine. The firm's offering is structured around investment management services rather than a traditional product portfolio, and it does not have named software products, modules, or technology offerings to enumerate.

Differentiator

Problem solved

Functional benefit

Products and services

  • Full Life Cycle Biotechnology Investment Management Fundamental, research-based equity investment management in specialized and precision medicine biotechnology companies across private and public markets, covering company building, early-stage, late-stage, and crossover-to-public investments. Service is provided to the firm's funds and their investors.
  • Private Equity Placements in Biotech Ventures Direct equity investments into private biotechnology companies, including participation as lead, co-lead, or co-investor in Series funding rounds, private placements, and structured financings (such as multi-tranche registered direct offerings tied to regulatory milestones).

Companies that use Boxer Capital

Customer profile

Segments1 record

Ideal customer profiles2 records

Boxer Capital technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Boxer Capital partnerships and signals

Strategic signal

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Boxer Capital competitors and assessment

Company assessment

Direct peers

  • Atlas Venture: Boston-based early-stage biotech fund builder with strong scientific orientation; comparable in portfolio construction philosophy to Boxer.
  • Venrock Healthcare: Healthcare-focused venture franchise with public-private crossover capabilities; overlaps with Boxer's biotech thesis investing.
  • EcoR1 Capital: Biotech-only crossover fund led by scientists/physicians investing across private and public equities; closely comparable to Boxer's specialist model.
  • RA Capital Management: Boston-based biotech-focused crossover fund investing across private and public markets with a science-driven diligence approach — directly comparable to Boxer's full life cycle biotech strategy.
  • Baker Bros. Advisors: Long-tenured biotech-only investment manager with deep scientific bench; competes with Boxer for precision medicine equity positions across stages.
  • OrbiMed: Healthcare-dedicated investment firm across private and public biotech; shares Boxer's specialization and cross-stage deployment model.
  • Foresite Capital: San Francisco-based healthcare and biotech specialist with crossover private-to-public investing; comparable in size and scientific thesis orientation.
  • ARCH Venture Partners: Early-stage biotech venture firm with deep scientific founder relationships; overlaps with Boxer's early-stage precision medicine focus.
  • Perceptive Advisors: Biotech-focused crossover fund deploying across private rounds and public equities; mirrors Boxer's public-private, life-cycle approach.
  • 5AM Ventures: Early-stage biotech venture firm with scientist-led diligence; comparable in scale and stage focus to Boxer's early-stage book.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Boxer Capital financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Boxer Capital leadership team

Management profile

Number of profiles

Profiles2 records

Boxer Capital funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Boxer Capital M&A and investment

M&A and investment

M&A

Investments131 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Boxer Capital

What does Boxer Capital do?

Boxer Capital Management is a full life cycle investment firm that provides venture capital and equity investment management to specialized and precision medicine biotechnology companies across private and public markets. The firm invests across all stages of the drug life cycle — from company building and early-stage through late-stage and crossover to public — using a fundamental, research-driven approach staffed by scientists with direct drug discovery experience.

Is Boxer Capital a public or private company?

Boxer Capital is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Boxer Capital founded?

Boxer Capital was founded in 2006. It employs 11 to 50 people.

Where is Boxer Capital based?

Boxer Capital is headquartered in San Diego, United States, in the North America region.

How does Boxer Capital make money?

One revenue line is on record: investment Management Fees.

Who are Boxer Capital's main competitors?

Direct peers on record are Atlas Venture, Venrock Healthcare, EcoR1 Capital, RA Capital Management, Baker Bros. Advisors, OrbiMed, Foresite Capital, ARCH Venture Partners, Perceptive Advisors and 5AM Ventures.

Does Boxer Capital have an API?

No public API is recorded for Boxer Capital.

What industry is Boxer Capital in?

Boxer Capital's product category is Biotechnology Venture Capital. Its primary akta.pro industry code is FSAAAIAA, Large-Cap Equity (Active). Its NAICS code is 52394 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Venture Capital Access OnlineFlare Therapeutics Secures $85M in Insider-Led Series C Financing and Appoints Anna Protopapas as Chief Executive OfficerFlare Therapeutics closed an $85 million Series C financing led by Third Rock Ventures and Nextech Invest, appointing Anna Protopapas as CEO. Proceeds will advance FX-111, an ARON degrader for prostate cancer, with FDA IND clearance and expected Phase 1A in Q3 2026.Investing.comClene Inc. ten percent owner sells $21k in stock By Investing.comUgwumba Chidozie, a ten percent owner of Clene Inc., sold 4,278 shares of the company's common stock on April 1, 2026, for a total transaction value of $21,261 at $4.97 per share, according to a Form 4 filing with the Securities and Exchange Commission. The sale occurred as Clene's stock experienced approximately 10% decline over the prior week, with the company currently trading at $4.89 and a market capitalization of $58.07 million. Separately, Clene has secured a registered direct offering of over $28 million to support its ALS drug candidate CNM-Au8, with participation from Boxer Capital, Coastlands Capital, and Vivo Capital, and has been granted an in-person FDA Type C meeting to discuss biomarker data.The Motley FoolInvestment Firm Doubles Down on Biotech Stock, Adds 386,000 Shares, According to Recent SEC FilingBoxer Capital Management, LLC disclosed in a February 17, 2026 SEC filing the purchase of 386,000 additional shares of Kodiak Sciences, representing an estimated $7.90 million trade based on quarterly average pricing. The Kodiak Sciences position increased by $19.49 million since the previous filing, bringing it to 7.0% of Boxer Capital's 13F reportable AUM as the firm's third-largest holding. Kodiak Sciences, a clinical-stage biopharmaceutical company developing therapeutics for retinal diseases, saw its shares rise 340% over the past year, significantly outperforming the S&P 500.Investing.comFDA grants Clene in-person meeting to discuss ALS drug biomarker data By Investing.comThe FDA has granted Clene Inc. an in-person Type C meeting to review biomarker data for its investigational ALS treatment CNM-Au8, with new analyses showing that a 9-10% reduction in neurofilament light chain (NfL) levels is associated with an 8-13% lower mortality risk in ALS patients, supporting NfL reduction as a potential surrogate endpoint for accelerated approval. Clene has also secured a $28 million registered direct offering involving Boxer Capital, Coastlands Capital, and Vivo Capital to fund operations through Q3 2026, while Benchmark has reiterated a Buy rating with a $31.00 price target following the positive biomarker findings. The company is preparing for an anticipated FDA New Drug Application submission in Q1 2026.BioSpaceClene Announces Registered Direct Offering of Over $28 MillionClene Inc. announced a registered direct offering of over $28 million priced above market under Nasdaq rules to new and existing investors, including Boxer Capital, Coastlands Capital, and Vivo Capital. The financing is structured in three tranches: an initial tranche of approximately $6.03 million, with two additional tranches totaling over $22 million contingent on FDA NDA acceptance and approval for CNM-Au8, the company's investigational ALS treatment. The company expects the funding to provide cash runway through potential FDA decision and into early 2027 for potential commercialization of CNM-Au8 in ALS.ScispotTop 20 Biotech Startups and Scaleups in San Diego in 2026The article presents a curated list of the top 20 biotech startups and scaleups in San Diego, highlighting their focus areas such as cell therapies, diagnostics, and medical devices. It notes that these companies benefit from a robust local ecosystem supported by venture capital firms like Boxer Capital LLC and Takeda Ventures Inc., as well as proximity to research institutions.MarketBeatBoxer Capital Management LLC Makes New Investment in Arvinas, Inc. (NASDAQ:ARVN)Boxer Capital Management LLC acquired a new stake in Arvinas, purchasing 1,058,614 shares worth about $20.3 million in Q4. The stake represents 1.7% of Boxer's portfolio and 1.54% of Arvinas. Analysts rate the stock a Moderate Buy with a consensus target of $34.33.MarketBeatBoxer Capital Management LLC Acquires New Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)Boxer Capital Management acquired a new position in SpringWorks Therapeutics during Q4, buying 3,421,541 shares worth about $123.6 million. The stake represents 10.4% of Boxer's portfolio and 4.6% of SpringWorks. Analysts rate the stock a Hold with a consensus price target of $52.57.MarketBeatBoxer Capital Management LLC Purchases New Shares in Keros Therapeutics, Inc. (NASDAQ:KROS)Boxer Capital Management acquired 250,000 shares of Keros Therapeutics in Q4, valued at about $3.96 million, giving it a 0.62% stake. Other institutional investors also increased positions, and the stock opened at $14.57. Analysts rate the stock a Moderate Buy with an average price target of $40.33.MarketBeatBoxer Capital Management LLC Acquires New Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX)Boxer Capital Management acquired a new position in Nurix Therapeutics during Q4, buying 563,067 shares valued at about $10.6 million. The company reported Q4 EPS of -$0.67, beating estimates of -$0.72, with revenue of $18.45 million. Analysts rate the stock a Moderate Buy with a consensus target of $30.44.